HUTCHMED (0013.HK)
Develops targeted cancer drugs and immunotherapies for patients worldwide
17.96+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-34.2%
The outlook
Hutchison China MediTech trades near the lower end of its 52-week range at 17.96. Analysts are strongly bullish with an average price target about 83% above current levels, though the stock's recent price trend is mixed relative to its moving averages. The company's low trailing P/E of 4.3 suggests a compressed valuation relative to analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 14 analysts
Price trendMixed vs its moving averages
52-week range16% of the way from its 52-week low to high
Price targetAvg target +83% vs current price
Analyst price target
~12-month · 14 analysts32.84average target+82.8% vs now
Now 17.96
Low 21.32High 51.93
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
30.75
52-wk low
15.57
50-day avg
17.68
200-day avg
21.41
Trailing P/E
4.3